Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
Article
Google Scholar
Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non–small cell lung cancer: a review. JAMA. 2019;322(8):764–74.
Article
CAS
Google Scholar
Hsu C-H, Tseng C-H, Chiang C-J, Hsu K-H, Tseng J-S, Chen K-C, Wang C-L, Chen C-Y, Yen S-H, Chiu C-H. Characteristics of young lung cancer: Analysis of Taiwan’s nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status. Oncotarget. 2016;7(29):46628.
Article
Google Scholar
Zhang Y-L, Yuan J-Q, Wang K-F, Fu X-H, Han X-R, Threapleton D, Yang Z-Y, Mao C, Tang J-L. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985.
Article
Google Scholar
Ruiz-Cordero R, Devine WP. Targeted therapy and checkpoint immunotherapy in lung cancer. Surg Pathol Clin. 2020;13(1):17–33.
Article
Google Scholar
Zhou F, Zhou C. Lung cancer in never smokers—the East Asian experience. Transl Lung Cancer Res. 2018;7(4):450.
Article
CAS
Google Scholar
Kim ES, Melosky B, Park K, Yamamoto N, Yang JC. EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations. Future Oncol. 2021;17(18):2395–408.
Article
CAS
Google Scholar
Yang JC-H, Wu Y-L, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu C-P, O’Byrne K, Feng J. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141–51.
Article
CAS
Google Scholar
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46.
Article
CAS
Google Scholar
Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013;24(1):54–9.
Article
CAS
Google Scholar
Apicella M, Giannoni E, Fiore S, Ferrari KJ, Fernández-Pérez D, Isella C, Granchi C, Minutolo F, Sottile A, Comoglio PM. Increased lactate secretion by cancer cells sustains non-cell-autonomous adaptive resistance to MET and EGFR targeted therapies. Cell Metab. 2018;28(6):848-865.e846.
Article
CAS
Google Scholar
Wu Y-L, Zhou C, Liam C-K, Wu G, Liu X, Zhong Z, Lu S, Cheng Y, Han B, Chen L. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015;26(9):1883–9.
Article
Google Scholar
Zhao Y, Wang H, He C. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: From mechanism analysis to clinical strategy. J Cancer Res Clin Oncol. 2021;147(12):3653–64.
Article
CAS
Google Scholar
Garg A, Batra U, Choudhary P, Jain D, Khurana S, Malik PS, Muthu V, Prasad K, Singh N, Suri T. Clinical predictors of response to EGFR-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: a real-world multicentric cohort analysis from India. Curr Probl Cancer. 2020;44(3):100570.
Article
Google Scholar
Buonerba C, Iaccarino S, Dolce P, Pagliuca M, Izzo M, Scafuri L, Costabile F, Riccio V, Ribera D, Mucci B. Predictors of outcomes in patients with EGFR-mutated non-small cell lung cancer receiving EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis. Cancers. 2019;11(9):1259.
Article
CAS
Google Scholar
Lambin P, Leijenaar RT, Deist TM, Peerlings J, De Jong EE, Van Timmeren J, Sanduleanu S, Larue RT, Even AJ, Jochems A. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14(12):749–62.
Article
Google Scholar
Scrivener M, de Jong EE, van Timmeren JE, Pieters T, Ghaye B, Geets X. Radiomics applied to lung cancer: a review. Transl Cancer Res. 2016;5(4):398–409.
Article
Google Scholar
Liao C-Y, Lee C-C, Yang H-C, Chen C-J, Chung W-Y, Wu H-M, Guo W-Y, Liu R-S, Lu C-F. Enhancement of Radiosurgical Treatment Outcome Prediction Using MRI Radiomics in Patients with Non-Small Cell Lung Cancer Brain Metastases. Cancers. 2021;13(16):4030.
Article
Google Scholar
Zwanenburg A, Vallières M, Abdalah MA, Aerts HJ, Andrearczyk V, Apte A, Ashrafinia S, Bakas S, Beukinga RJ, Boellaard R. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295(2):328–38.
Article
Google Scholar
Cucchiara F, Del Re M, Valleggi S, Romei C, Petrini I, Lucchesi M, Crucitta S, Rofi E, De Liperi A, Chella A. Integrating liquid biopsy and radiomics to monitor clonal heterogeneity of EGFR-positive non-small cell lung cancer. Front Oncol. 2020;10:593831.
Article
Google Scholar
Park BW, Kim JK, Heo C, Park KJ. Reliability of CT radiomic features reflecting tumour heterogeneity according to image quality and image processing parameters. Sci Rep. 2020;10(1):1–13.
CAS
Google Scholar
Goodyear MD, Krleza-Jeric K, Lemmens T. The declaration of Helsinki. Br Med J Publishing Group. 2007;335:624–5.
Article
Google Scholar
Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.
Article
Google Scholar
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D’Amico TA, Dilling TJ. NCCN guidelines insights: non–small cell lung cancer, version 4.2016. J Natl Compr Cancer Netw. 2016;14(3):255–64.
Article
Google Scholar
Dhruv B, Mittal N, Modi M. Study of Haralick’s and GLCM texture analysis on 3D medical images. Int J Neurosci. 2019;129(4):350–62.
Article
Google Scholar
García-Olalla Ó, Fernández-Robles L, Alegre E, Castejón-Limas M, Fidalgo E. Boosting texture-based classification by describing statistical information of gray-levels differences. Sensors. 2019;19(5):1048.
Article
Google Scholar
Lu C-F, Hsu F-T, Hsieh KL-C, Kao Y-CJ, Cheng S-J, Hsu JB-K, Tsai PH, Chen R-J, Huang C-C, Yen Y. Machine learning–based radiomics for molecular subtyping of gliomas. Clin Cancer Res. 2018;24(18):4429–36.
Article
Google Scholar
Mao KZ. Orthogonal forward selection and backward elimination algorithms for feature subset selection. IEEE Trans Syst Man Cybern B (Cybern). 2004;34(1):629–34.
Article
CAS
Google Scholar
Katzman JL, Shaham U, Cloninger A, Bates J, Jiang T, Kluger Y. DeepSurv: personalized treatment recommender system using a Cox proportional hazards deep neural network. BMC Med Res Methodol. 2018;18(1):1–12.
Article
Google Scholar
Bergstra J, Bengio Y. Random search for hyper-parameter optimization. J Mach Learn Res. 2012;13(2):281–305.
Dixon PM. Bootstrap resampling. In: Encyclopedia of environmetrics. 2006.
Google Scholar
Weibull W. A statistical distribution function of wide applicability. J Appl Mech. 1951;18:290–3.
Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A. Treatment of non–small-cell lung cancer with erlotinib or gefitinib. N Engl J Med. 2011;364(10):947–55.
Article
CAS
Google Scholar
Bersanelli M, Tiseo M, Artioli F, Lucchi L, Ardizzoni A. Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis. Anticancer Res. 2014;34(6):3185–8.
CAS
Google Scholar
Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai C-M, Tan EH. Ho JC-M, Chu DT, Zaatar A: Impact of EGFR inhibitor in non–small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst. 2013;105(9):595–605.
Article
CAS
Google Scholar
Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, Riely GJ. Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung CancersMechanisms of Acquired Resistance to EGFR-TKI Therapy. Clin Cancer Res. 2013;19(8):2240–7.
Article
CAS
Google Scholar
Li H, Zhang R, Wang S, Fang M, Zhu Y, Hu Z, Dong D, Shi J, Tian J. CT-based radiomic signature as a prognostic factor in stage IV ALK-positive non-small-cell lung cancer treated with TKI crizotinib: a proof-of-concept study. Front Oncol. 2020;10:57.
Article
CAS
Google Scholar
Song J, Shi J, Dong D, Fang M, Zhong W, Wang K, Wu N, Huang Y, Liu Z, Cheng Y. A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI TherapyPrediction of EGFR-TKI Treatment Outcome in Stage IV NSCLC. Clin Cancer Res. 2018;24(15):3583–92.
Article
CAS
Google Scholar
Jin R, Peng L, Shou J, Wang J, Jin Y, Liang F, Zhao J, Wu M, Li Q, Zhang B. EGFR-mutated squamous cell lung cancer and its association with outcomes. Front Oncol. 2021;11:2262.
Google Scholar
Masters GA, Temin S, Azzoli CG, Giaccone G, Baker S Jr, Brahmer JR, Ellis PM, Gajra A, Rackear N, Schiller JH. Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33(30):3488.
Article
CAS
Google Scholar
Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest. 2017;151(1):193–203.
Article
Google Scholar
Watanabe T, Kinoshita T, Itoh K, Yoshimura K, Ogura M, Kagami Y, Yamaguchi M, Kurosawa M, Tsukasaki K, Kasai M. Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas. Leuk Lymphoma. 2010;51(5):813–21.
Article
CAS
Google Scholar
Li K-j, Gu W-y, Xia X-f. Zhang P, Zou C-l, Fei Z-h: High Mean corpuscular volume as a predictor of poor overall survival in patients with esophageal cancer receiving concurrent chemoradiotherapy. Cancer Manag Res. 2020;12:7467.
Article
CAS
Google Scholar
Kim Y-I. Will mandatory folic acid fortification prevent or promote cancer? Am J Clin Nutr. 2004;80(5):1123–8.
Article
CAS
Google Scholar
Ren JH, He WS, Yan GL, Jin M, Yang KY, Wu G. EGFR mutations in non-small-cell lung cancer among smokers and non-smokers: A meta-analysis. Environ Mol Mutagen. 2012;53(1):78–82.
Article
CAS
Google Scholar
Apostolova I, Rogasch J, Buchert R, Wertzel H, Achenbach HJ, Schreiber J, Riedel S, Furth C, Lougovski A, Schramm G. Quantitative assessment of the asphericity of pretherapeutic FDG uptake as an independent predictor of outcome in NSCLC. BMC Cancer. 2014;14(1):1–10.
Article
Google Scholar
van Cruijsen H, Giaccone G, Hoekman K. Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies. Int J Cancer. 2005;117(6):883–8.
Article
Google Scholar